Infant Bacterial Therapeutics AB (publ) (STO:IBT.B)
Sweden · Delayed Price · Currency is SEK 67.50
+2.50 (3.85%)
Aug 13, 2026, 5:29 PM CET
STO:IBT.B Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 131.93 | 144.01 | 223.39 | 329.06 | 335.84 | 386.75 |
Cash & Short-Term Investments | 131.93 | 144.01 | 223.39 | 329.06 | 335.84 | 386.75 |
Cash Growth | -31.20% | -35.53% | -32.11% | -2.02% | -13.16% | -8.66% |
Other Receivables | 1.58 | 2.79 | 4 | 2.97 | 1.47 | 1.2 |
Total Trade Receivables | 1.58 | 2.79 | 4 | 2.97 | 1.47 | 1.2 |
Other Current Assets | 1.67 | 6.81 | 3.22 | 9.53 | 1.72 | 9.14 |
Total Current Assets | 135.18 | 153.61 | 230.61 | 341.56 | 339.03 | 397.09 |
Other Intangible Assets | 7.87 | 8.07 | 8.89 | 9.7 | 10.52 | 11.33 |
Long-Term Investments | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.05 |
Total Assets | 143.11 | 161.75 | 239.57 | 351.33 | 349.62 | 408.48 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 46.43 | 43.86 | 46.99 | 30.07 | 8.75 | 4.8 |
Accrued Expenses | 13.72 | 12.17 | 21.89 | 15.33 | 8.67 | 7.65 |
Other Current Liabilities | 0.39 | 0.39 | 0.42 | 0.78 | 0.5 | 0.78 |
Total Current Liabilities | 60.54 | 56.42 | 69.3 | 46.18 | 17.91 | 13.22 |
Total Liabilities | 60.54 | 56.42 | 69.3 | 46.18 | 17.91 | 13.22 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 3.67 | 3.67 | 3.67 | 3.67 | 3.06 | 3.06 |
Additional Paid-in Capital | 768.84 | 768.84 | 768.84 | 766.83 | 670.93 | 669.02 |
Retained Earnings | -689.94 | -667.18 | -602.25 | -465.35 | -342.28 | -276.83 |
Shareholders' Equity | 82.58 | 105.33 | 170.26 | 305.15 | 331.71 | 395.25 |
Total Liabilities & Equity | 143.11 | 161.75 | 239.57 | 351.33 | 349.62 | 408.48 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 131.93 | 144.01 | 223.39 | 329.06 | 335.84 | 386.75 |
Net Cash Growth | -31.20% | -35.53% | -32.11% | -2.02% | -13.16% | -8.66% |
Net Cash Per Share | 9.79 | 10.69 | 18.07 | 26.61 | 29.92 | 34.45 |
Book Value | 82.58 | 105.33 | 170.26 | 305.15 | 331.71 | 395.25 |
Book Value Per Share | 6.13 | 7.82 | 13.77 | 24.68 | 29.55 | 35.21 |
Tangible Book Value | 74.71 | 97.26 | 161.38 | 295.45 | 321.19 | 383.92 |
Tangible Book Value Per Share | 5.55 | 7.22 | 13.05 | 23.89 | 28.61 | 34.20 |